Qnexa

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2011
0120092011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
 
Is this relevant?
Review
2012
Review
2012
On 22 February 2012, the U.S. Food and Drug Administration (FDA) convened a panel for advice on a proposed antiobesity medication… (More)
Is this relevant?
Review
2012
Review
2012
Obesity has important adverse health consequences associated with multiple metabolic, structural, degenerative, neoplastic, and… (More)
Is this relevant?
Review
2012
Review
2012
Antiobesity medications have a weighty history in the US. Throughout the post-war era, amphetamines were widely touted for their… (More)
Is this relevant?
Review
2012
Review
2012
Obesity, the primary health threat in the 21st century, affects the quality of life physiologically, economically and… (More)
  • table 1
  • table 2
Is this relevant?
2011
2011
Qnexa (VI-0521) is an investigational fixed-dose combination drug of phentermine and topiramate currently in Phase III clinical… (More)
Is this relevant?
Review
2010
Review
2010
When diet and exercise alone don’t work, people struggling with obesity sometimes turn to weight loss drugs. Existing medications… (More)
Is this relevant?
Review
2010
Review
2010
When diet and exercise alone don’t work, people struggling with obesity sometimes turn to weight loss drugs. Existing medications… (More)
Is this relevant?
Review
2010
Review
2010
In this review we assess the range of centrally active anorectics that are either in human clinical trials, or are likely to be… (More)
Is this relevant?
Review
2009
Review
2009
The anti-obesity field has received a boost in recent months following the announcement of promising Phase III trial data for… (More)
  • table 1
Is this relevant?